drugset / Trial / NCT04969224
A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on cough and physical activity using wearable technology in CF participants.
Timeline
- Start
- 2021-10-12
- Primary completion
- 2022-07-26
- Completion
- 2022-07-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivacaftor | Other / unclassified | 150 mg | Oral |
| Subject | elexacaftor | Small molecule | 200 mg | Oral |
| Subject | tezacaftor | Other / unclassified | 100 mg | Oral |